The anthracycline glycoside natural products are a class of molecules with potent antineoplastic activities that have attracted attention over the years for treatment of cancer. FDA-approved drugs in this class include doxorubicin (DOX), daunorubicin, epirubicin, and idarubicin (Scheme 1A), but cardiotoxicity and multidrug resistance limit their use as chemotherapeutics. While DOX surpassed a market value of $1.08 billion in 2020, its toxicity and unclear mechanism of action make the search for less toxic compounds with comparable activity attractive.